Literature DB >> 20195562

[When only the pathologist may help. Limitation and possibilities of biopsies in Internal Medicine].

R Knüchel-Clarke1, H H Lutz, J Floege, N Marx, T H Brümmendorf, C Trautwein.   

Abstract

Histological evaluation after biopsy remains the gold standard for the diagnosis of numerous diseases in Internal Medicine. The gastrointestinal tract (e. g. esophagus, liver and large intestine), the kidneys or bone marrow are organs, where biopsy-driven diagnosis and evaluation of therapeutic regimens are of major relevance. Improvement in blood analysis, endoscopic techniques and radiology could significantly reduce the number of biopsies. Hence under certain circumstances, the risk of biopsy can be avoided and non-invasive markers can sufficiently substitute the histological evaluation. However, histological evaluation derived from biopsies remains the standard of diagnosis in many cases in Internal Medicine. In the present review the current standards and future developments of pathologic diagnosis through biopsy are illustrated.

Entities:  

Mesh:

Year:  2010        PMID: 20195562     DOI: 10.1007/s00108-009-2453-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus.

Authors:  Herbert C Wolfsen; Julia E Crook; Murli Krishna; Sami R Achem; Kenneth R Devault; Ernest P Bouras; David S Loeb; Mark E Stark; Timothy A Woodward; Lois L Hemminger; Frances K Cayer; Michael B Wallace
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

2.  Our approach to a renal transplant biopsy.

Authors:  R John; A M Herzenberg
Journal:  J Clin Pathol       Date:  2009-10-22       Impact factor: 3.411

3.  Safety and adequacy of renal transplant protocol biopsies.

Authors:  Anke Schwarz; Wilfried Gwinner; Markus Hiss; Joerg Radermacher; Michael Mengel; Hermann Haller
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

4.  The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria.

Authors:  Prateek Sharma; John Dent; David Armstrong; Jacques J G H M Bergman; Liebwin Gossner; Yoshio Hoshihara; Janusz A Jankowski; Ola Junghard; Lars Lundell; Guido N J Tytgat; Michael Vieth
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

5.  EUS-guided sampling of suspected GI stromal tumors.

Authors:  Katherine M Hoda; Sarah A Rodriguez; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2009-04-25       Impact factor: 9.427

6.  Risk management of renal biopsy: 1387 cases over 30 years in a single centre.

Authors:  P Stratta; C Canavese; M Marengo; P Mesiano; L Besso; M Quaglia; D Bergamo; G Monga; G Mazzucco; G Ciccone
Journal:  Eur J Clin Invest       Date:  2007-12       Impact factor: 4.686

7.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 8.  Focal liver lesions: contrast-enhanced ultrasound.

Authors:  Tommaso Vincenzo Bartolotta; Adele Taibbi; Massimo Midiri; Roberto Lagalla
Journal:  Abdom Imaging       Date:  2009 Mar-Apr

9.  Timing of complications in percutaneous renal biopsy.

Authors:  William L Whittier; Stephen M Korbet
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

10.  European evidence-based Consensus on the management of ulcerative colitis: Special situations.

Authors:  Livia Biancone; Pierre Michetti; Simon Travis; Johanna C Escher; Gabriele Moser; Alastair Forbes; Jörg C Hoffmann; Axel Dignass; Paolo Gionchetti; Günter Jantschek; Ralf Kiesslich; Sanja Kolacek; Rod Mitchell; Julian Panes; Johan Soderholm; Boris Vucelic; Eduard Stange
Journal:  J Crohns Colitis       Date:  2008-01-28       Impact factor: 10.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.